News and innovations published by German exhibitorsback to overview
LDL-c direct FS, a new homogeneous assay for the direct determination of LDL-cholesterol (LDL-C) is one of the latest products in the DiaSys portfolio. LDL-C is used as part of the lipid panel to estimate the risk of developing heart disease and to guide and monitor lipid-lowering therapies. Atherosclerotic cardiovascular disease starts early in life, often during childhood without symptoms and signs. Studies revealed that 71% and 43% of middle-aged men and women, respectively, show evidence of subclinical atherosclerosis. Evidence from epidemiologic, genetic, and clinical intervention studies have clearly demonstrated that low-density lipoprotein is causal in this process.
LDL-c direct FS is characterized by a wide measuring range and shows good overall precision at clinical cut-off points. The ready-to-use reagent may be applied on all automated clinical chemical analyzers and shows good comparability with commercially available methods for the determination of LDL-cholesterol.
Exhibitor: DiaSys Diagnostic Systems GmbH
We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection